NasdaqGS:IBRXBiotechs
How Investors May Respond To ImmunityBio (IBRX) Bladder Cancer Milestone And EMA Backing For ANKTIVA
ImmunityBio recently reported that its immunotherapy ANKTIVA, used with standard BCG, showed sustained disease-free and progression-free survival with a favorable safety profile in BCG-unresponsive non-muscle invasive bladder cancer, while the European Medicines Agency recommended conditional marketing authorization for ANKTIVA plus BCG in the EU for carcinoma in situ.
Together with the appointment of industry veteran Bruce Wendel to the board, these advances deepen ImmunityBio’s clinical...